While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

The study lasts up to five weeks and involves four to five visits to the Center for Human Nutrition. The study involves measuring body composition, sleep, mood, diet and other aspects of health.

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

An hour of moderate-intensity exercise reduced sensations of hunger in people with overweight and obesity in a recent study.

Moderate-intensity exercise helps regulate appetite and boosts key weight loss hormones, offering benefits similar to weight ...

Gastrointestinal adverse events partially mediated the weight loss effects among patients with obesity who received tirzepatide vs placebo.

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

A new study conducted by researchers from the University of Eastern Finland the Karolinska Institutet explored the ways that ...